COVID-19 Impact on Chronic Respiratory Conditions

The emergence of COVID-19 has had profound implications for individuals with chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung diseases. SARS-CoV-2 exploits airway entry factors and provokes inflammatory cascades, exacerbating underlying pathology. Patients with COPD and interstitial lung disease experience modestly elevated risks of hospitalisation and mortality, reflecting diminished pulmonary reserve and heightened inflammatory tone. Asthma presents a more nuanced picture: well controlled cases exhibit risk profiles similar to the general population, whereas those with recent exacerbations or high-dose inhaled corticosteroid use may face greater vulnerability. Molecular studies reveal that type 2 and antiviral interferon responses dynamically regulate key viral receptors in the airway epithelium, influencing susceptibility. Globally, these insights inform stratified patient management, emphasising optimisation of baseline therapy, early antiviral intervention and targeted modulation of airway inflammation. Ongoing research continues to refine risk stratification, elucidate mechanisms of long-term sequelae and guide public health priorities for vaccination and shielding strategies in at-risk respiratory cohorts.

Research from Nature Portfolio

Recent work has elucidated how airway inflammation shapes SARS-CoV-2 tropism. One study demonstrated that interleukin-13-driven type 2 inflammation markedly upregulates the serine protease TMPRSS2 within secretory networks, whereas interferon responses to respiratory viruses amplify ACE2 expression at both mRNA and protein levels. Genetic variation in these entry factors further modulates individual susceptibility across populations. In parallel, a nationwide cohort analysis found that pre-existing asthma per se did not increase the risk of respiratory failure or death from COVID-19 after adjustment for comorbidity burden. Importantly, asthma patients with an acute exacerbation in the year preceding infection exhibited higher mortality, underscoring the need for tight control of baseline disease to mitigate COVID-19 severity.

COVID-19 Impact on Chronic Respiratory Conditions publication trend

The graph below shows the total number of articles in covid-19 impact on chronic respiratory conditions across all publications each year (not limited to Nature Index journals).

Technical terms

ACE2 receptor: A membrane‐bound enzyme on airway epithelial cells that serves as the primary entry point for SARS-CoV-2.

TMPRSS2: A host serine protease that primes viral spike protein, facilitating cell entry.

Type 2 inflammation: An immune response driven by cytokines (e.g. interleukin-4, ‑5, ‑13) often associated with asthma and allergic disease.

Inhaled corticosteroids (ICS): Anti‐inflammatory medications delivered to the airway to control chronic respiratory disease.

Acute exacerbation: A sudden worsening of baseline respiratory symptoms often requiring additional treatment or hospitalisation.

References

1. Regulation of angiotensin-converting enzyme 2 isoforms by type 2 inflammation and viral infection in human airway epithelium. Mucosal Immunology (2023).
2. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. The Lancet Respiratory Medicine (2021).
3. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nature Communications (2020).